These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19058313)

  • 21. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory signals mediated by programmed death-1 are involved with T-cell function in chronic periodontitis.
    Figueira EA; de Rezende ML; Torres SA; Garlet GP; Lara VS; Santos CF; Avila-Campos MJ; da Silva JS; Campanelli AP
    J Periodontol; 2009 Nov; 80(11):1833-44. PubMed ID: 19905953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.
    Fisicaro P; Valdatta C; Massari M; Loggi E; Biasini E; Sacchelli L; Cavallo MC; Silini EM; Andreone P; Missale G; Ferrari C
    Gastroenterology; 2010 Feb; 138(2):682-93, 693.e1-4. PubMed ID: 19800335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
    Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM
    Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells.
    Ke M; Zhang Z; Xu B; Zhao S; Ding Y; Wu X; Wu R; Lv Y; Dong J
    Int Immunopharmacol; 2019 Oct; 75():105824. PubMed ID: 31437792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis.
    Raptopoulou AP; Bertsias G; Makrygiannakis D; Verginis P; Kritikos I; Tzardi M; Klareskog L; Catrina AI; Sidiropoulos P; Boumpas DT
    Arthritis Rheum; 2010 Jul; 62(7):1870-80. PubMed ID: 20506224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of ulinastatin on immune function of spleen in severely burned rats and its mechanism].
    Li J; Hu C; Yao Y; Yang H
    Zhonghua Shao Shang Za Zhi; 2016 May; 32(5):266-71. PubMed ID: 27188484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-1/PD-L1 expression on CD(4+) T cells and myeloid DCs correlates with the immune pathogenesis of atrial fibrillation.
    Liu L; Zheng Q; Lee J; Ma Z; Zhu Q; Wang Z
    J Cell Mol Med; 2015 Jun; 19(6):1223-33. PubMed ID: 25810125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of PD-L1 blockade on function of dendritic cells derived from chronic myelocytic leukemia].
    Wang CY; Zhang LS; Tian FQ; Huang R
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1146-9. PubMed ID: 18928614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atorvastatin Attenuates Programmed Death Ligand-1 (PD-L1) Induction in Human Hepatocellular Carcinoma Cells.
    Shwe TH; Pothacharoen P; Phitak T; Wudtiwai B; Kongtawelert P
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
    Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis.
    Jurado JO; Alvarez IB; Pasquinelli V; Martínez GJ; Quiroga MF; Abbate E; Musella RM; Chuluyan HE; García VE
    J Immunol; 2008 Jul; 181(1):116-25. PubMed ID: 18566376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of programmed death 1 ligands by murine T cells and APC.
    Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H
    J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses.
    Bennett F; Luxenberg D; Ling V; Wang IM; Marquette K; Lowe D; Khan N; Veldman G; Jacobs KA; Valge-Archer VE; Collins M; Carreno BM
    J Immunol; 2003 Jan; 170(2):711-8. PubMed ID: 12517932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects.
    Xu L; Zhang Y; Tian K; Chen X; Zhang R; Mu X; Wu Y; Wang D; Wang S; Liu F; Wang T; Zhang J; Liu S; Zhang Y; Tu C; Liu H
    J Exp Clin Cancer Res; 2018 Oct; 37(1):261. PubMed ID: 30373602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-7 enhances anti-tumor activity of CD8
    Teng D; Ding L; Cai B; Luo Q; Wang H
    Cytokine; 2019 Jun; 118():115-123. PubMed ID: 29655570
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-35 Dampens CD8
    Yang L; Shao X; Jia S; Zhang Q; Jin Z
    Front Immunol; 2019; 10():1032. PubMed ID: 31134088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease.
    Trabattoni D; Saresella M; Pacei M; Marventano I; Mendozzi L; Rovaris M; Caputo D; Borelli M; Clerici M
    J Immunol; 2009 Oct; 183(8):4984-93. PubMed ID: 19794071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1.
    He B; Yan F; Wu C
    Biomed Pharmacother; 2018 Feb; 98():95-101. PubMed ID: 29247952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.